Johnson & Johnson ordered to pay $5.7 million in California mesh trial

Reuters, 5 March 2015
Author: Jessica Dye
“A California jury on Thursday ordered Johnson & Johnson’s Ethicon Inc unit to pay $5.7 million in the first trial over injuries blamed on the TVT Abbrevo, one of numerous transvaginal mesh products that are the subject of thousands of lawsuits.”
Find article here.

Nurofen maker faces court over ACCC claim ads are misleading

SMH, 5 March 2015
Sources: AAP
“The company that markets Nurofen faces legal action over claims it has misled consumers about the popular painkiller. The Australian Competition and Consumer Commission alleges that Reckitt Benckiser’s Nurofen Specific Pain Products are identical, despite being advertised to treat different kinds of pain, such as migraines and tension headaches.”
Find article here.

FDA issues warning on testosterone-boosting drugs

CBS News, 4 March 2015
AP
“The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related issues like low libido and fatigue. The agency says drugmakers must clearly state in their labeling and promotions that the drugs, currently taken by millions of U.S. men, are only approved to treat low testosterone levels caused by disease or injury, not normal aging.”
Find article here.

Flu pandemic: Will antiviral drugs like Tamiflu protect us?

ABC Catalyst, 4 March 2015
Author: Maryanne Demasi
“Around 2,000 Australians die each year from the flu. During a pandemic, the potential death toll is far higher. Antiviral drugs were thought to be an effective weapon against influenza. But it now turns out this was based on incomplete evidence. Nonetheless, governments around the world have spent millions of dollars stockpiling these medications in preparation for a pandemic.”
Find article here.

Orexigen Released Interim Data Without Approval Of Trial Leaders

Forbes, 3 March 2015
Author: Larry Husten
“Orexigen Therapeutics disclosed positive results from a clinical trial of Contrave, its weight loss pill. The surprising thing about the Orexigen disclosure, is that it consisted of data derived from an interim analysis of the company‚Äôs ongoing Light trial. Normally, interim results are performed by an independent data monitoring committee and the results are known only to the members of the DMC. But the detailed results of the analysis are never made public until the trial is stopped.”
Find article here.

SEC warns pharma companies to be honest about FDA correspondence

Reuters, 3 March 2014
Author: Sarah N Lynch
“The U.S. Securities and Exchange Commission’s top enforcement chief warned on Tuesday that too many pharmaceutical companies are failing to accurately portray their dealings with federal drug regulators – a problem that could get them in trouble.”
Find article here.